drugset / Trial / NCT07230496

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants

NCT07230496

Phase 1 Recruiting 104 enrolled Laekna Limited
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE103 injection in healthy overweight/obese participants or healthy postmenopausal women. Study will also evaluate the safety, tolerability and preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants. In addition, the study will also investigate the safety, tolerability of a single-dose co-administration of LAE102 and LAE103 in healthy overweight/obese participants.

Timeline

Start
2025-12-30
Primary completion
2028-03-20
Completion
2028-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject LAE102 Unknown Subcutaneous
Subject LAE103 Unknown Subcutaneous

Indications

No indication recorded.